CARISMA THERAPEUTICS ($CARM) is expected to release its quarterly earnings data on Tuesday, April 8th after market close, per Finnhub. Analysts are expecting revenue of $5,528,400 and earnings of -$0.17 per share.
You can see Quiver Quantitative's $CARM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CARISMA THERAPEUTICS Hedge Fund Activity
We have seen 13 institutional investors add shares of CARISMA THERAPEUTICS stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TPG GP A, LLC removed 561,442 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $235,131
- HRT FINANCIAL LP added 36,902 shares (+inf%) to their portfolio in Q4 2024, for an estimated $15,454
- WEXFORD CAPITAL LP removed 34,861 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $14,599
- TWO SIGMA INVESTMENTS, LP removed 34,141 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $14,298
- VANGUARD GROUP INC removed 29,399 shares (-2.0%) from their portfolio in Q4 2024, for an estimated $12,312
- RENAISSANCE TECHNOLOGIES LLC added 24,600 shares (+11.9%) to their portfolio in Q4 2024, for an estimated $10,302
- UBS GROUP AG added 24,083 shares (+11047.2%) to their portfolio in Q4 2024, for an estimated $10,085
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CARISMA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $CARM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- EF Hutton issued a "Buy" rating on 10/30/2024
To track analyst ratings and price targets for CARISMA THERAPEUTICS, check out Quiver Quantitative's $CARM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
